Oncology Drug Development and Dose Optimization: What Are the Implications of Project Optimus?
HTML-код
- Опубликовано: 15 окт 2024
- More on this story: xtalks.com/onc...
Xtalks spoke with Matthew Confeld, Assistant Director of Clinical Research Methodology at Worldwide Clinical Trials, about what the FDA’s Project Optimus means for oncology programs.
At Worldwide, Dr. Confeld provides strategic scientific, medical and regulatory support services to sponsors across all phases of drug development.
He explains that all sponsors, whether they are developing cytotoxic or targeted therapies, and anyone involved in early-phase clinical research, must be aware of and adhere to the FDA’s new requirements, as these represent the agency’s current expectations.
Receive weekly news and webinar updates right in your inbox: xtalks.com/reg...
Listen live and interact with featured speakers on our upcoming Life Science webinars: bit.ly/2YRzAV0
#clinicalresearch #clinicaltrials #oncology #oncologytrials #cancer #fda
